paclitaxel

Resultados alentadores de los balones cubiertos de Biolimus para el tratamiento de vasos pequeños

Using Biolimus-Coated Balloons for Treating Small-Vessel Disease Yields Promising Results

Drug-eluting balloons have demonstrated safety and effectiveness in the treatment of small-vessel coronary artery disease and in-stent restenosis. However, randomized studies were performed using paclitaxel. Several studies have shown that using biolimus, a semisynthetic analog of sirolimus, optimizes drug delivery in both stents and balloons. The aim of this randomized, multicenter study was to evaluate<a href="https://solaci.org/en/2022/06/13/using-biolimus-coated-balloons-for-treating-small-vessel-disease-yields-promising-results/" title="Read more" >...</a>

Más stents suman evidencia al esquema corto y nos acercamos al “efecto de clase”

Revascularization Using DES in Infrapopliteal Disease: Meta-Analysis and Change of Paradigm?

Peripheral vascular disease (PVD) has been under-studied and under-recognized in comparison with ischemic heart disease and stroke, despite its well-known impact on quality of life and its associated morbidity and mortality. According to a systematic review, it was estimated that in 2015 about 238 million people globally had PVD. This number is on the rise.<a href="https://solaci.org/en/2022/06/01/revascularization-using-des-in-infrapopliteal-disease-meta-analysis-and-change-of-paradigm/" title="Read more" >...</a>

Los balones farmacológicos pasaron la prueba del tiempo en territorio femoropoplíteo

Drug-Eluting Balloons Find Their Niche

According to this large European registry, drug-eluting balloons (DEBs) are competing with drug-eluting stents (DES) to treat in-stent restenosis. Drug-eluting balloons seem to work equally well for the treatment of long-term in-stent restenosis compared with new stent implantation (for the thin-strut DES registry). If DEBs can compete with DES—adding to the advantage of avoiding a<a href="https://solaci.org/en/2021/10/13/drug-eluting-balloons-find-their-niche/" title="Read more" >...</a>

ELUVIA: DES en territorio femoropoplíteo con lesiones complejas

ELUVIA: DES in Complex Femoropopliteal Lesions

Paclitaxel-eluting stent Eluvia showed promising results after two years with a revascularization freedom rate of 80% despite the fact that these were complex femoropopliteal lesions. As the safety of paclitaxel-eluting devices becomes more consistent, more studies on its efficacy are being published. Back in 2018, the safety of paclitaxel-eluting balloons and stents was under scrutiny<a href="https://solaci.org/en/2021/06/12/eluvia-des-in-complex-femoropopliteal-lesions/" title="Read more" >...</a>

ACC 2021 | VOYAGER PAD: utilidad del rivaroxaban luego de una angioplastia periférica

ACC 2021 | VOYAGER PAD: Usefulness of Rivaroxaban After Peripheral Angioplasty

Patients with peripheral vascular disease who undergo angioplasty in the lower limbs find benefit from treatment with rivaroxaban, according to the VOYAGER PAD study, presented at the scientific sessions of the American College of Cardiology (ACC) 2021 Congress and simultaneously published in JACC. Patients with said disease present a higher risk of ischemic events not<a href="https://solaci.org/en/2021/05/21/acc-2021-voyager-pad-usefulness-of-rivaroxaban-after-peripheral-angioplasty/" title="Read more" >...</a>

Efecto a largo plazo de los balones liberadores con bajas dosis de paclitaxel

Global FFR as Prognosis in CAD Patients without Ischemia

Global fractional flow reserve (FFR) results from adding up FFR values of the three major coronary arteries. This figure represents the physiological atherosclerosis burden and can predict events at long term in patients without stenosis leading to ischemia. This recent study published in JAHA looked at major cardiovascular events (death, infarction and revascularization) at 5<a href="https://solaci.org/en/2020/12/16/global-ffr-as-prognosis-in-cad-patients-without-ischemia/" title="Read more" >...</a>

El éxito de la angioplastia sobre las CTO por reestenosis disminuye la mortalidad cardíaca

In-Stent Restenosis Treatment: Meta-Analysis of 10 Randomized Studies

The best strategy to treat in stent restenosis continues to be a dilemma. A new drug eluting stent (DES) seems to be the simplest treatment, even though it adds metal layers that will make it harder and harder to retreat. Drug coated balloons might be a viable alternative seeing as it seems to enable retreatment,<a href="https://solaci.org/en/2020/11/18/in-stent-restenosis-treatment-meta-analysis-of-10-randomized-studies/" title="Read more" >...</a>

balon farmacologico

Drug-Coated Balloons in Critical Ischemia: The Paradigm of Randomized Evidence vs. Logbooks

This research, which included thousands of patients treated for chronic inferior limb ischemia with drug-coated balloons, did not show an association between said devices and the increased mortality observed in some randomized trials.&nbsp; The long-term evidence from plenty of real-world patients contradicts what has been shown in randomized trials, leaving an information gap. Endovascular revascularization<a href="https://solaci.org/en/2020/10/13/drug-coated-balloons-in-critical-ischemia-the-paradigm-of-randomized-evidence-vs-logbooks/" title="Read more" >...</a>

balon farmacologico

IN.PACT AV ACCESS | Drug-Coated Balloons for Dialysis Fistulas

The IN.PACT AV Access study, recently published in the New England Journal of Medicine (NEJM), showed that drug-coated balloons are superior for the treatment of stenotic lesions in arteriovenous fistulas for dialysis compared with conventional balloons. Dialysis fistulas are an unknown territory for paclitaxel-eluting balloons, since the formal recommendation in the guidelines is conventional angioplasty<a href="https://solaci.org/en/2020/09/30/in-pact-av-access-drug-coated-balloons-for-dialysis-fistulas/" title="Read more" >...</a>

SOLACI PERIPHERAL | 3rd Clinical Case: Femoral PCI

In keeping with its Clinical Case Discussion Program, SOLACI’s peripheral interventions department, SOLACI Peripheral, presents the third clinical case, to promote knowledge exchange across the entire Latin American hemodynamics community.&nbsp; Share your thoughts on case and resolution in the comments and answer the questions at the end of the article. Femoral PCI Authors:&nbsp;MD Mauricio Cavalieri<a href="https://solaci.org/en/2020/08/24/solaci-peripheral-3rd-clinical-case-femoral-pci/" title="Read more" >...</a>

Top